TRPV4 activity modulates cell activities including receptor trafficking and transcriptional or translational regulations. We tested its CRISPR/Cas9 scissor efficacy in HepG2 (HEK293) cell noticed that it worked well in both cell lines to eliminate TRPV4 genome sequences. To confirm TRPV4 functions in the cell morphology maintenance and cell growth (beyond Ca 2+ channel), we compared its wound healing, cell surface area, survival property and soft agar growth ability after deletion of TRPV4 gene in the cells with its CRISPR/Cas9 system. With these experiments, we confirmed that TRPV4 is required not only to function as Ca 2+ channel but also to maintain its proper cell morphology as a corner stone protein on the cell adhesion junction.
Introduction
The TRPV4 channel, a member of the transient receptor potential (TRP) vanilloid subfamily, is expressed in a broad range of tissues where it involves the generation of a Ca 2+ signal and/or depolarization of membrane potential [1] [2] [3] [4]. TRPV4 is known as a polymodal receptor that transfers many noxious stimuli into electric signals and is subject to extensive modulation by neurotransmitters, inflammatory cytokines, growth factors, local hormones, and oxidative chemicals, thereby serving as an integration device for processing nociceptive information [4] [5] [6] [7] . The channel contains its distinct cytoplasmic domains to transduce various modulatory inputs into channel activity, which ulti-mately adjusts excitability of sensory afferents as a substrate of many cellular signaling pathways [8] [9] [10] . This human TRPV4 gene is found in chromo-some12, at q24.1. The gene has 15 exons. C and D: the mRNA consists of 3229 bases, whereas the TRPV4 protein, contains 839 amino [11] [12] .
TRPV4 is known to be activated by moderate temperature, endogenous arachidonic acid metabolites, and phorbol esters including the inactive 4α-phorbol 12,13-didecanoate (4-αPDD), and involved in receptor-operated Ca 2+ entry, thus known as polymodal channel. TRPV4 is also stimulated by the mechano-and osmo-transducing messenger 5'-6'-epoxyeicosatrienoic acid (EET). Therefore the role of TRPV4 in osmo-and mechano-transduction contributes to important functions including cellular and systemic volume homeostasis, arterial dilation, nociception, epithelial hydroelectrolyte transport, bladder voiding, and ciliary beat frequency regulation. Ligand binding to each site either directly gates the channel or triggers conformation changes that secondarily modulate thresholds of channel opening by other modalities [13] [14] [15] [16] [17] .
To modulate TRPV4 subcellular localization and/or function, several proteins are also identified including microtubule-associated protein 7, calmodulin, with no lysine protein kinases, STIM1, PACSIN3, E-cadherin, N-cadherin, and α-catenin, actin, tubulin [17] [18] [19] . In addition, a close functional and physical interaction exists between the inositol triphosphate receptor 3 (IP3R3) and analysis of the gating mechanism of TRPV4 activation for even a single modality is hindered by incomplete understanding of coupling processes among different modes of channel activation [20] [21] [22] [23] .
The TRPV4-related pathologies may open a new way to cure the human diseases related with TRPV4 mutations. The mammalian TRPV4 channel has distinct binding sites for small chemical agonists, including endogenous fatty acid or vanilloids, 2-aminoethoxy-diphenyl borate, and purine nucleotides, as well as large macromolecular ligands such as calmodulin or inositide phospholipids. Further, results from animal studies suggest that TRPV4 antagonism has therapeutic potential in oedema, pain, gastrointestinal disorders, and lung diseases such as cough, bronchoconstriction, pulmonary hypertension, and acute lung injury. TRPV4 knockout mice and several synthetic pharmacological compounds that selectively target TRPV4 are now available, which has allowed detailed investigation into the therapeutic potential of this ion channel. TRPV4 mutations are dispersed throughout most domains of the gene. There is no domain-specific phenotype in TRPV4-associated skeletal dysplasias. More than 50 human genetic diseases related with TRPV4 mutations have been reported, including two mutation hot spots (one is the codon for P799 in exon 15, and the other is the codon for R594 in exon 11) [ In the course of our work of TRPV4 role in the human cancer cells whether it promotes or not the tumor cell growth, we designed 5 different guide RNA (GR)s for human TRPV4 genome (NM 021625) for the gene scissor of TRPV4 to remove its gene [24] . HepG2 cell was also used to test the gene scissor efficacy American Journal of Molecular Biology and noticed its efficacy in HepG2 to eliminate TRPV4 genome sequences. After TRPV4 genome sequences was completely destroyed (or removed 8 bp, in theory) with TRPV4 CRISPR/Cas9 system, we compared its wound healing and cell morphology and tumorigenicity, before/after deletion of TRPV4 gene with its CRISPR/Cas9 scissor system to conformed TRPV4 functions in HepG2 cell [25] [26] . Our results suggested that TRPV4 seems to be required to maintain cell attachment with the extracellular matrix/or neighbor cell membrane to block its metastasis and to be necessary for wound healing in HepG2 cell with CRISPR/Cas9 scissor system [27] . Thus, we suggest here that the novel role for TRPV4 has been established as a suppressor protein in HepG2 cell to inhibit metastasis or the epithelial-mesenchymal transition (EMT). Further TRPV4 scissor which seems to be useful as a genetic tool of TRPV4-induced dominant positive human diseases should be also considered more carefully.
Results
Human TRPV4 removal with its CRISPR/Cas9 scissor (RG7/cas9): The putative structure of TRPV4 (WT, Gene Bank no. BC127052) was shown in Figure   1 rich domain (PRD) for pacsin binding and ankylin (A) repeat domain. We designed 5 RNA guides for its CRISPR/Cas9 scissor following the guide program [24] [27] , and tested its efficacy in HepG2 cell. The corresponding nucleic acid sequence and the frame position are indicated ( Figure 1(b) ).
The efficacy of TRPV4 Scissor to delete its target gene: To test the ability whether TRPV4 RNA guide gene (RG) directs Cas9-mediated deletion in human HepG2 cells, the mismach sensitive nuclease assay (T7E1 assay) was performed after co transfecting each TRPV4 RG and Cas9 expression vector in the cell (total 1 μg dRGEN and Cas9 plasmid in 24 well). The genomic DNA was prepared after 48 h post-tansfection. Negative control (N) is the PCR product (647 bp PCR product) with PCR primers in Figure 1 . Bottom figure represents the reaction without T7E1 for the control of above result. As shown in Figure 2 (a), we observed all 4 guide (RG) effectively deleted TRPV4 genome in HepG2 cell. Among them, the most effective RG7 cccaggcgatgggcgaccaaatc 177 -199 bp; reverse frame was chosen for the next experiment. To determine whether TRPV4 channel protein expression was deleted by RG7 TRPV4 and pGEM Cas9 CMV expression vector, Western blot was performed with the immunoprecipitant with TRPV4 antibody after treatment with RG7 TRPV4 and pGEM Cas9 CMV. As expected, TRPV4 was successfully unexpressed in HepG2 (Figure 2 (b) left) which was transfected with RG7 TRPV4 and pGEM Cas9 CMV, compared with the background HepG2 cell (Figure 2 (b) right). To confirm further, calcium image experiment was executed. As shown in Figure 2 (c), Ca 2+ live image in HepG2 cell in the presence of 4α-PDD which was used as the TRPV4 specific activator was reduced from 204 ± 22 (Arbitrary Unit) to 50 ± 6, by TRPV4 scissor treatment. Together these results, the treatment with RG7 TRPV4 and pGEM Cas9 CMV to HepG2 cell successfully ablated its endogenous TRPV4 gene.
HepG2 morphology change by TRPV4 scissor treatment: Previously we demonstrated that the interaction of TRPV4 with actin (or tubulin) is differentially regulated by its 824 serine phosphorylation of TRPV4 [28] . In the line of this observation, we hypothesized that TRPV4 deletion also affects the cell morphology through the alteration of interaction between TRPV4 and cytoskeletal protein such as actin or tubulin. In confocal microscopic observation, we observed that PCC value between tubulin (red) and TRPV4 (green) was 0.68 ± 0.06 (N = 5), suggesting the protein-protein interaction between these two proteins is also normally in HepG2 cell (Figure 3(a) ). By the way, with TRPV4 RG7 (green)/Cas9 treatment, tubulin (red) subcellular localization was not web network form but it accumulated under the plasma membrane. The cell morphology was also changed as a round shape Moreover, the cell surface area (2.1 ± 0.3 μm 2 : N = 5) was also reduced from the untransfected cell (4.2 ± 0.2 μm 2 ; N = 5). Therefore these results suggested that the deletion of TRPV4 contributes the change of tubulin organization and cell morphology together with E-cadherin expression reduction (Figure 3(d) ).
Further, since TRPV4 is also known as a component protein in cell adherent junction to maintain cell morphology [29] , next we examine the cell morphological To test the abilities of TRPV4 RNA guide gene (RG) to direct Cas9-mediated deletion in human HepG2 cells, we performed the mismach sensitive nuclease assay (T7E1 assay), after cotransfecting TRPV4 RG and Cas9 expression vector in the cell (total 1 μg dRGEN and Cas9 plasmid in 24 well). The genomic DNA was prepared at 48 h post-tansfection. The star maker represents the expected cut pattern according to each RG with T7E1 assay (left table). N: Negative control is the PCR product (647 bp PCR product) with primers in Figure 1 . Bottom figure represents the reaction without T7E1 for the control of above result. (b) HepG2 cells which express their endogenous TRPV4 were transiently transfected with EGFP-TRPV4 WT and Cas9 plasmid. After 48 h the cells were lysated, and immunoprecipitation was conducted with mouse anti-TRPV4 antibody. Western blot assays were performed with rabbit anti-TRPV4. The endogenous TRPV4 (MW: ~130 Kd) of HepG2 cell (left lane) was undetectable in TRPV4 RG7/Cas9 treated cell (right lane). (c) In HepG2 cells, the endogenous TRPV4 was successfully deleted by treatment of TRPV4 RNA guide gene (RG) and Cas9 expression. Ca 2+ live image in HepG2 cell in the presence of 4α PDD was reduced from 204 ± 22* (Arbitrary Unit) to 50 ± 6*, through TRPV4 scissor treatment (after one day later). *p value less than 0.05.
change and E-cadherin subcellular localization after deletion TRPV4 with its gene scissor (Figure 3 (c)). Consistent with the above results (Figure 3(b) ), the average surface area of the green colored cells which were affected by TRPV4 RG7 (green)/Cas9 was reduced as a half of that of untransfected cells. Furthermore, the surroundings of green colored cell were not attached with E-cadherin (red), while that of untransfected cells were attached with E-cadherin (red). These results suggested that E-cadherin expression was down regulated in green colored cell which was transfected with TRPV4 RG7/Cas9. Together, these results suggested that not only TRPV4 RG7 (green)/Cas9 treatment was successfully operated in HepG2 cell, but also the deletion of TRPV4 resulted in the cell morphology (Figure 3(d) ). Therefore, TRPV4 seems to be the major corner stone protein for its plasma membrane attachment with other cytoskeletal proteins including E-cadherin and tubulin thereby providing a link to the actin cytoskele-ton in Figure 5 [14] [17] [28] [29] [30] .
The enhancement of cell growth, soft ager growth ability and wound healing by TRPV4 scissor treatment: To determine whether the elimination of interaction between TRPV4 and E-cadherin (actin, α/β catenin or tubulin) promotes its cell growth, soft agar growth ability and wound healing [28] [29], we compared each ability of TRPV4 scissor treated HepG2 cells with that of background cell.
After TRPV4 gene scissor (EGFP RG7/Cas9), or EGFP vector was transfected, the rate of apoptosis was measured by FACS (Table 1) . Unexpectedly, the apoptotic effect of TRPV4 gene scissor was reduced to a half that of the EGFP vector alone transfected cell ( Table 1 ). Because the removal of TRPV4 genome in HepG2 cell by TRPV4 gene scissor promotes the cell growth, the role of TRPV4 seems to be an anti-growth gene. To access further the role of TRPV4 in the cell growth, we measured the effect of TRPV4 activity on the wound healing with the transfected HepG2 cell with TRPV4 RG7/Cas9 (Figure 4(d)) . Surprisingly, we observed that the wound steak width of untreated HepG2 was 6.2 ± 0.2 (N = 5), that of transfected HepG2 with TRPV4 RG7/Cas9 was 2.1 ± 0.3 (μm; N = 5) after 72 hr incubation, suggesting that the transfected HepG2 with TRPV4 RG7/Cas9 grew 3 time faster than the untreated cell did (Figure 4 ).
In order to define TRPV4 role in the tumor, we compared the soft agar growth (colony forming) ability of TRPV4 gene scissor treated cell with its background HepG2 cell (Table 2 ). TRPV4 gene scissor (EGFP TRPV4 RG7/Cas9), or EGFP vector was transfected and the growth (colony forming) ability on the soft agar after 500 cells plating. After 3 week, we detected that only the cells treated with TRPV4 gene scissor formed the cell colony on the soft agar (7 ± 2; N = 5). Because the deletion of TRPV4 promotes the malignancy of HeG2 cell, the channel seems to play a role as tumor suppressor protein [28] [29] .
In summary, with TRPV4 gene scissor, we demonstrated here the presence of TRPV4 roles as a corner stone to maintain the native pseudopod shape and it inhibits cell extravasation and EMT. Therefore, TRPV4 plays a key role as a corner stone to assemble the cytoskeleton such as tubulin or microtubule in the plasma membrane to maintain cell proper shape. The interaction between TRPV4 and the cytoskeletal protein (actin, α/β catenin or tubulin) regulates the proper cell shape or EMT through E-cadherin expression reduction ( Figure 5 ). However, our results support that the expression of TRPV4 reduces both EMT and tumorigenesis ( [4] . Other researcher study did, however, concede that the "gain of function" of the mutant channels could be the result of more effective channel insertion of mutant TRPV4 proteins. However, the data in other study of CMT 2C also supports the proposition that "gain of function" of mutant TRPV4, rather than "loss of function" of these mutant channels, is pathologically important [4] [11] . Both mutant TRPV4 receptors have normal physiological localization within the cells expressing them.
Discussion
Cells transfected with these mutant TRPV4 receptors have elevated intracellular Ca 2+ levels, and cell death can be reversed by ruthenium red. Thus, it still seems to be controversial how TRPV4 mutation contributes cell growth. Therefore, many results suggested that the mechanism of action of the TRPV4 mutants involves a "gain of function" of the ion channel likely to lead to increased intracellular Ca 2+ concentration.
Among many TRPV4 mutants, the two hot spot mutants (V620I, P799R) cause the metatropic dyslpasia by the gain function [1] [2] [3] [4] . The result seems to be varied, depending on the cell line which is used in experiment and experiment condition. Even though many TRPV4 point mutant humans suffer many genetic diseases, the TRPV4 knockout mouse has no obvious symptom.
Thus, we rationalize that the "gain of function" of mutant TRPV4 can be cured by the genetic scissor to remove the point mutant TRPV4 which caused each specific human genetic disease. Therefore, to remove TRPV4 genome, we design the specific TRPV4 genetic scissor with the several guide RNA expression vector (Figure 1(b) ). Subsequently, we succeed to remove TRPV4 genome in HepG2 cell HEK293 and HCT116 (colon cancer cell line: data not shown). Consequently, we assume that the "gain of function" of mutant TRPV4 can be cured by the genetic scissor to remove the mutant TRPV4.
Recently, researchers revealed that TRPV4-expressing cancer cells are softer and that TRPV4-conferred cell deformability was associated with actin depolymerization, VASP phosphorylation and inversely correlated with the activation of ERM and Cofilin [29] . However, our observation suggested that the deletion of TRPV4 enhances its wound healing, cell deformability, soft agar growth, and metastasis. Therefore, upregulation of TRPV4 seems to be anti-cancer protein in our system.
Other researchers also reported that the down regulation of TRPV4 is a key determinant of tumor endothelial cell tumor angiogenesis and abnormal vasculature [30] [31] [32] . This study also supports a role for TRPV4 in metastasis by regulating cancer cell stiffness and cytoskeleton at the cell cortex. Our result seems to be support TRPV4 role in the metastasis inhibition by the strength its adhesion junction ( Figure 5 ). However, further studies will be required to clarify the TRPV4 role in metastasis. To test this hypothesis further, we are comparing now the tumor metastasis in TRPV4 knockout mouse with that in WT mouse.
We subsequently measured cell surface area expansion with TRPV4 scissor treatment to access whether TRPV4 knockdown affects cell shape or morphology. As compared TRPV4 scissor, the cell surface area of WT remained unchanged, whereas that of was significantly increased. It has been characterized that TRPV4
links to E-cadherin through catenin. So we expected that if TRPV4 was deleted in the cell by its scissor, the cell adhesion with E-cadherin was also blocked. As expected, the transfected cell with TRPV4 scissor (green color) was not attached with E-cadherin and the cell morphology was round shape. Therefore, TRPV4
seems to contribute the cell shape formation as the corner stone on the plasma membrane. TRPV4 is characterized as the mechanoreceptor in bladder urothelium and skin epithelial cell. To do that, it should connect with cytoskeletal protein such as actin and tubulin. The N-terminal of TRPV4 is responsible to associated with a/b catenin proteins [1] . We observed that the web matrix formation of tubulin was destroyed by TRPV4 scissor treatment, and the tubulin in the cell was localized in the edge of cell. Therefore, the results also support that TRPV4
as the corner stone on the plasma membrane contributes as the mechanoreceptor which associates with the cytoskeletal proteins. Once again, the confocal re-American Journal of Molecular Biology sults confirmed that TRPV4 scissor can work properly to remove the target genome.
TRPV4 is expressed at a higher level in tumor-derived endothelial cells when compared with normal endothelial cells [25] . TRPV4 is important in the migration of the former cell type but not in relation to the latter. This, in turn, causes elevation of the level of TRPV4 found in the plasma membrane. This increased level of TRPV4 in the plasma membrane is believed to be important in promoting endothelial cell migration which results in angiogenesis and tumor growth.
On the other hand, the level of TRPV4 found in healthy or inflamed skin keratinocytes is reduced in premalignant lesions and in non-melanoma skin cancer, although whether this is a component of the mechanism of the disease remains unknown.
TRPV4 seems to be down-regulated during metastasis to detach from the basal attachment with extracellular matrix or neighbor cell (Figures 3-5 ). Therefore our results support that TRPV4 seems to be one of anti-metastatic Ca 2+ channel ( Table 1 and Table 2 ). We assumed that the down regulation of TRPV4 seems to promote the release of α/β-catenin from the adherent junction, and the free β-catenin which is translocated to the nuclear stimulates the cell proliferation, like Wnt signaling ( Figure 5 ). In addition, because the use of TRPV4 CRISPR/Cas9 scissor has been shown to remove out TRPV4 genome successfully in HEK293 and HCT116 (colon cancer cell line: data not shown) cell, this scissor can be also useful to genetic treatment of TRPV4-induced dominant positive diseases with its gene scissor. However, we cannot rule out the possibility that TRPV4 crisper/cas9 delete the tumor suppressor gene during its working in the cell and cell became more mutagenesis.
The epithelial-mesenchymal transition (EMT) is defined as a process by which epithelial cells lose their cell polarity and cell-cell adhesion, and gain migratory and invasive properties to become mesenchymal stem cells; these are multipotent stromal cells that can differentiate into a variety of cell types. Thus, EMT is essential for numerous developmental processes including mesoderm formation and neural tube formation. EMT has also been characterized to occur in wound healing, in organ fibrosis and in the initiation of metastasis in cancer progression. Because TRPV4 removal by its genetic scissor enhanced HepG2 cell wound healing and its soft agar growth through the downregulation or disrupt E-cadherin organization (Figure 3 and Figure 4 , Table 1 ), the channel protein seems to be involved in the EMT process. Therefore, because TRPV4 seems to be a target protein to be downregulated for the EMT, TRPV4 may be regarded as a tumor suppresser protein ( Figure 5 ).
Because the deletion of endogenous TRPV4 by its scissor enhances its tumorigenicity in breast and colon cancer, the proper TRPV4 function seems to be required for its antitumor activity. TRPV4 is expressed at a lower level in tumor-derived endothelial cells when compared with normal endothelial cells [25] [ 26] . TRPV4 which is defined as a Ca 2+ channel functions as not only the physi-cal connecting protein between E-cadherin in AJ and intracellular cytoskeleton protein on plasma membrane to maintain cell shape but also the inhibitor on the liver cancer metastasis [23] [29] [30] . However, we assumed that TRPV4 deletion contributes to the cell growth by increasing free cellular-catenin which is otherwise hold by TRPV4 under the plasma membrane. The deletion effect of TRPV4 activity with was also determined by whole-cell Ca 2+ image analysis in transiently transfected HepG2 cells. Even though the regulation of cell stiffness and cell cortex dynamics are putative modes of actions through which TRPV4 promotes cancer cell extravasation, the upregulation of TRPV4 may be a viable drug target for management of metastatic liver cancers [29] [30] .
In conclusion, we demonstrated here with TRPV4 CRISPR/Cas9 system that the channel which plays role as Ca 2+ /Mg 2+ ion transporter, also has a role for the corner stone to connect physically between E-cadherin and the intracellular cytoskeleton protein with the plasma membrane to maintain cell shape ( Figure 5 ).
In addition, TRPV4 functions as the suppressor of metastasis or EMT to maintain the integrate cell shape, with attaching the neighboring cell in AJ.
Materials and Methods
Cell Culture: HepG2 was cultured with DMEM supplemented with 10% newborn calf serum and antibiotics. Cells were transfected with 400 ng wild-type or mutant receptors with or without 50 ng enhanced GFP plasmids using Turbofect reagents (Fermentas). Confocal Microscopy: HepG2 cells were seeded overnight at 60% confluence onto culture slides coated with human fibronectin (Becton Dickinson, MA). The cells were washed several times with ice-cold PBS and fixed in 3% paraformaldehyde for 10 minutes. The fixed cells were permeabilized with 0.1% Triton X-100 for 10 minutes and blocked for 1 hours in PBS containing 5% BSA (Sigma, USA) and 0.1% Tween. Following incubation with a polyclonal antibody against E-cadherin or monoclonal antibody against TRPV4, the cells were washed and stained further with a conjugated donkey anti-rabbit IgG prior to processing the slides for immunofluorescence. After an additional 20 minutes of incubation at 37˚C, the cells were fixed, permeabilized, and decorated with either an anti-E-cadherin or TRPV4 antibody. As a secondary antibody, Alexa Significance: TRPV4 contributes to maintain its proper cell morphology and migration as a cornerstone protein
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